For type 2 diabetes mellitus. ANDA 213320, held by Harman Finochem. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 213320 (Metformin Hydrochloride), held by Harman Finochem, was first approved by FDA on Dec 3, 2021, with 2 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2021 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 26, 2023 | Supplement 2Manufacturing | Approved | None posted |
| Dec 3, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters